IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma
Sha Zhu, … , Dina Kandil, Leslie M. Shaw
Sha Zhu, … , Dina Kandil, Leslie M. Shaw
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e97398. https://doi.org/10.1172/jci.insight.97398.
View: Text | PDF
Research Article Oncology

IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma

Abstract

Pleomorphic invasive lobular carcinoma (PILC) is an aggressive variant of invasive lobular breast cancer that is associated with poor clinical outcomes. Limited molecular data are available to explain the mechanistic basis for PILC behavior. To address this issue, targeted sequencing was performed to identify molecular alterations that define PILC. This sequencing analysis identified genes that distinguish PILC from classic ILC and invasive ductal carcinoma by the incidence of their genomic changes. In particular, insulin receptor substrate 2 (IRS2) is recurrently mutated in PILC, and pathway analysis reveals a role for the insulin receptor (IR)/insulin-like growth factor-1 receptor (IGF1R)/IRS2 signaling pathway in PILC. IRS2 mutations identified in PILC enhance invasion, revealing a role for this signaling adaptor in the aggressive nature of PILC.

Authors

Sha Zhu, B. Marie Ward, Jun Yu, Asia N. Matthew-Onabanjo, Jenny Janusis, Chung-Cheng Hsieh, Keith Tomaszewicz, Lloyd Hutchinson, Lihua Julie Zhu, Dina Kandil, Leslie M. Shaw

×

Figure 5

IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma cells.

Options: View larger image (or click on image) Download as PowerPoint
IRS2 mutations linked to invasion in pleomorphic invasive lobular carci...
(A) Immunoblots of cell extracts from KEP 1.11 murine pleomorphic invasive lobular carcinoma (PILC) cells stably expressing shGFP and 2 independent shRNA targeting Irs2 (shIrs2-1 and shIrs2-2). (B) Cells grown in a Matrigel/collagen I gel were scored for the distance of invasive branching (mean ± SD, n = 50 colonies from 1 of 2 representative experiments). (C) KEP 1.11 cells expressing shGFP were serum starved and pretreated with DMSO or BMS-754807 at the concentrations indicated for 4 hours and stimulated with insulin-like growth factor-1 (IGF-1; 50 ng/ml) for 30 minutes. Cell extracts containing equivalent amounts of protein were immunoblotted with antibodies specific for insulin receptor substrate 2 (IRS2), pIGF1R (Y1135/1136)/pIR (T1150/1151), IGF1R, pAkt (S473), Akt, or Tubulin. (D) Cells grown in a Matrigel/collagen I gel were treated with DMSO or BMS-754807 (BMS, 100 nM) on day 3 and scored for the distance of invasive branching on day 7 (mean ± SD, n = 50 colonies from a representative experiment). (E) Immunoblots of cell extracts from KEP 1.11 cells stably expressing empty vector (pCDH), wild-type human IRS2 (WT), or the IRS2 mutants identified in PILC. Cells grown in a Matrigel/collagen I gel were scored for (F) the extent of invasion (mean ± SD of 3 independent experiments) or (G) the distance of invasive branching (mean ± SD, n = 50 colonies from 1 of 3 representative experiments). Representative images for each cell line are shown. (H) Cell migration assay using Transwell culture chambers (mean ± SD of 3 independent experiments). (I) Glucose uptake assay (mean ± SD of 4 independent experiments). Student’s t test was performed between pCDH and WT-IRS2, and 1-way ANOVA with Bonferroni post hoc testing was performed for all other comparisons. *P < 0.05, ***P < 0.001, relative to pLKO.1 or pCDH control; #P < 0.05, ##P < 0.01, ###P < 0.001, relative to WT-IRS2. Scale bar: 20 μm.